Blackstone Explores $2 Billion Sale of ZO Skin Health

M&A · PartnershipCorporate Action
โดย Insider Monkey·US·Read original
Summary · why it matters

Blackstone Inc. is exploring a possible sale of ZO Skin Health, the medical-grade skincare company founded by dermatologist Dr. Zein Obagi, in a deal that Reuters reported could value the business at around $2 billion. The process is still in the early stages, and Blackstone is working with Citigroup and Raymond James on the potential sale. ZO sells cleansers, serums, and exfoliators mainly through doctors and skincare professionals, a physician-led distribution model that gives the brand a clinical, premium image and could attract strategic buyers. Reuters pointed to recent deals such as L'Oréal's $4.7 billion purchase of Kering's beauty business and Henkel's $1.4 billion acquisition of Olaplex as evidence that buyers will still spend heavily on brands with strong growth potential. The $2 billion figure remains only a reported target, and there is no guarantee Blackstone will reach that price or complete a deal, with weak buyer interest potentially forcing a discount or prompting the firm to hold the asset.

Impact on stocks 7

Consumer Staples▲ · 2 stocks
Artificial Intelligence▲ · 1 stocks
Blackstone Group Inc
BX
± MixedCapitalrelevance

Blackstone is exploring a ~$2B sale of ZO Skin Health, an M&A/divestiture event, but the deal is early-stage with no guarantee of completion or price.

Digital Finance & Tokenization▲ · 1 stocks
Citigroup Inc.
C
± MixedCapitalrelevance

Citigroup is named as an advisor working with Blackstone on the potential ZO Skin Health sale, but no fee or outcome is specified.

Financials▲ · 1 stocks
Raymond James Financial Inc.
RJF
± MixedCapitalrelevance

Raymond James is named as an advisor working with Blackstone on the potential ZO Skin Health sale, but no fee or outcome is specified.

Consumer Discretionary▲ · 1 stocks
Others▲ · 1 stocks

Off-coverage companies 1

ZO Skin HealthPrivate± Mixed
relevance

© 2026 MarketDXNews